294
Participants
Start Date
June 30, 2015
Primary Completion Date
May 31, 2016
Study Completion Date
March 31, 2017
MYL-1401A (Adalimumab)
MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
Humira® (Adalimumab)
Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
Mylan Investigational Site 102, Plovdiv
Mylan Investigational Site 105, Plovdiv
Mylan Investigational Site 101, Sevlievo
Mylan Investigational Site 100, Sofia
Mylan Investigational Site 103, Sofia
Mylan Investigational Site 107, Tallinn
Mylan Investigational Site 108, Tallinn
Mylan Investigational Site 109, Tallinn
Mylan Investigational site 110, Tallinn
Mylan Investigational Site 106, Tartu
Mylan Investigational SIte 112, Tartu
Mylan Investigational Site 127, Budapest
Mylan Investigational Site 128, Budapest
Mylan Investigational Site 125, Debrecen
Mylan Investigational Site 129, Gyula
Mylan Investigational Site 126, Szekszárd
Mylan Investigational Site 131, Bialystok
Mylan Investigational Site 137, Bialystok
Mylan Investigational Site 135, Iwonicz-Zdrój
Mylan Investigational Site 140, Krakow
Mylan Investigational Site 139, Lodz
Mylan Investigational Site 133, Olsztyn
Mylan Investigational Site 138, Poznan
Mylan Investigational Site 136, Warsaw
Mylan Investigational Site 130, Wroclaw
Mylan Investigational Site 132, Wroclaw
Mylan Investigational Site 134, Wroclaw
Mylan investigational site 156, Kazan'
Mylan Investigational site 155, Penza
Mylan Investigational Site 148, Ryazan
Mylan Investigational Site 149, Saint Petersburg
Mylan Investigational site 159, Kharkiv
Mylan investigational site 161, Uzhhorod
Lead Sponsor
Mylan GmbH
INDUSTRY
Mylan Inc.
INDUSTRY